The development of new chemical entities (NCEs) with antiproliferative activity targeting the BCR-ABL gene is pivotal in advancing the treatment of chronic myeloid leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.